Clinical Trials
560 trialsStudy of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
CaDAnCe-101
BeOne Medicines
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
BeOne Medicines
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Grit Biotechnology
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
A Phase 2 Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
Guangzhou Lupeng Pharmaceutical Company LTD.
A Phase Ib/II Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Guangzhou Lupeng Pharmaceutical Company LTD.
BELLWAVE-011
Merck Sharp & Dohme LLC
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
BeOne Medicines
MK-2140-006
Merck Sharp & Dohme LLC
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Eli Lilly and Company
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Curis, Inc.
REALITY-RO
Janssen Research & Development, LLC
MAJIC
AstraZeneca
AQUALIS
AstraZeneca
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Eli Lilly and Company
BELLWAVE-010
Merck Sharp & Dohme LLC
CLL registry
AstraZeneca
Soundtrack-E
AstraZeneca
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Newave Pharmaceutical Inc
KEYNOTE145
Acerta Pharma BV
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie
SIGMA
Grifols Biologicals, LLC
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Acerta Pharma BV
A Rollover Study of CC-122
Bristol-Myers Squibb
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
BeOne Medicines
CaDAnCe-302
BeOne Medicines
CaDAnCe-303
BeOne Medicines
CAN3001
Janssen Research & Development, LLC
GLOW
Janssen Research & Development, LLC
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Janssen Research & Development, LLC
TAILOR
Janssen Research & Development, LLC
QOLIBRI
Janssen Cilag S.A.S.
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Acerta Pharma BV
EPCOREâ„¢ NHL-1
Genmab
EPCOREâ„¢ NHL-3
Genmab
EPCOREâ„¢ CLL-1
Genmab
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical Inc
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
AbbVie
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies
Ascentage Pharma Group Inc.
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
PROVIDENCE
AbbVie
TITANium
AstraZeneca
BRUIN CLL-321
Eli Lilly and Company
ARISE
AstraZeneca
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
AstraZeneca